Fangsheng Pharmaceutical Group 1.1 new chemical drug diantikang sodium for injection approved clinical

According to the latest information from CFDA, a new chemical drug with acceptance No "cxhl1301089 Xiang" of Fangsheng pharmaceutical has been approved for clinical application At present, the processing status is changed to "certificate preparation completed - pending approval" It is found that the product is diantikang sodium for injection, which belongs to class 1.1 chemical new drug It is a derivative of camptothecin and used for anti-tumor This product was applied for acceptance in the drug administration in December 2013 In 2014, the annual report disclosed that the company's research project "phase I and phase II clinical research of diantikang on colorectal cancer" was approved as a major national new drug creation project Some analysts pointed out that this kind of anti-tumor drugs will become a "nuclear weapon" for Hunan Fangsheng pharmaceutical to seize the national and even global market.